Consistency of Carbopol 971-P NF gels and influence of soluble and cross-linked PVP.

A study is made of the polymerization process of polyacrylic acid, commercially known as Carbopol 971 NF, assessing its consistency as a function of the degree of neutralization at pH values from 3 to 12, approximately. Percentage concentrations ranging from 0.1 to 1.4% (w/w) were studied. The gels obtained were non-Newtonian, and pseudoplastic. As concentration and pH rise, the consistency of the gels increase to a maximum, which appears between pH 6 and 8, allowing their use as vehicles in bioadhesive formulations for mucosal application. Over the increasing viscosity interval, functions were obtained to indicate the consistency of the gel as a function of pH and concentration. Since the correlation between the theoretical and experimental results is excellent, the equation found can be used to theoretically calculate the working concentration and pH required to secure the necessary consistency for a given vehicle. The addition of soluble polyvinylpyrrolidone (PVP), and cross-linked PVP (PVPP) does not substantially modify the rheological behavior of the gels, thus permitting their addition to usual vehicles.

Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones.

A preliminary study attempting to predict the intrinsic absolute bioavailability of a group of antibacterial 6-fluoroquinolones-including true and imperfect homologues as well as heterologues-was carried out. The intrinsic absolute bioavailability of the test compounds, F, was assessed on permanently cannulated conscious rats by comparing the trapezoidal normalized areas under the plasma concentration-time curves obtained by intravenous and oral routes (n = 8-12). The high-performance liquid chromatography analytical methods used for plasma samples are described. Prediction of the absolute bioavailability of the compounds was based on their intrinsic rat gut in situ absorption rate constant, k(a). The working equation was: where T represents the mean absorbing time. A T value of 0.93 (+/-0.06) h provides the best correlation between predicted and experimentally obtained bioavailabilities (F' and F, respectively) when k(a) values are used (slope a = 1.10; intercept b = -0.05; r = 0.991). The k(a) values can also be expressed in function of the in vitro partition coefficients, P, between n-octanol and a phosphate buffer. In this case, theoretical k(a) values can be determined with the parameters of a standard k(a)/P correlation previously established for a group of model compounds. When P values are taken instead of k(a) values, reliable bioavailability predictions can also be made. These and other relevant features of the method are discussed.

Validation of a biophysical drug absorption model by the PATQSAR system.

Absorption rate constants (in situ rat gut technique) and in vitro antibacterial activities of twenty fluoroquinolones have been evaluated. A biophysical model that relates the absorption of the compounds with their lipophilicity was fitted. The model considers the absorption process from the intestinal lumen as the sum of two resistances in series: aqueous diffusional barrier and lipoidal membrane. Even if partitioning into the membrane and membrane diffusion are both enhanced for lipophilic compounds, the absorption rate constant is limited by the aqueous diffusion. To estimate the influence of structural modifications on each property and to establish the role of lipophilicity in controlling in situ absorption and in vitro antibacterial activity, the PATQSAR search system is used to construct structure-property relationships. The structural models, which explain 99% of the total variance of each physicochemical property and 96% of each in vitro biological activity, provide an explicit and precise interpretation of lipophilicity, absorption, and antimicrobial activity. The results confirm the important role of lipophilicity in controlling absorption, as pointed out by the biophysical model for the piperazinyl series, and suggest the introduction of electronic factors in order to extend the model to heterologues. They also justify the mechanism by which quinolones are assumed to induce antibacterial activity.

Influence of chronic alcohol intake on intestinal taurine and antipyrine transport in pregnant rats.

Taurine is a nonessential amino acid that plays a critical role in development. However, biosynthetic capacity is almost negligible in the fetus and must be supplied by the mother. Therefore, when maternal taurine status is depressed during gestation, fetal tissue taurine concentrations can also be compromised. In the present study, the effect of chronic alcohol intake on the intestinal transport of taurine during pregnancy has been investigated by an in vitro technique that allows measurement of the unidirectional influx of the amino acid across the intact rat mid jejunum. The influence of alcohol intake on the passive component of the intestinal transport was also investigated with antipyrine, a model compound for passive diffusion. For chronic alcohol treatment, the rats were fed a liquid diet containing ethanol (36% of calories) or an isocaloric diet (pair-fed control) for 5 weeks before and during pregnancy. The animals were sacrificed at 21 days of gestation. Results from the kinetic analysis revealed that chronic ethanol treatment significantly decreases the maximum transport (Jm) of taurine, without modifying the Michaelis-Menten constant (Km), but enhances its diffusion component (ka) compared with that of controls. At the same time, this treatment significantly increased the passive diffusion of antipyrine. These results indicate that although chronic ethanol inhibits the active transport of taurine, passive diffusion is significantly increased. However, because of the predominant passive component in the intestinal absorption of taurine, an overall enhancement in the absorption of this amino acid is observed in alcohol-fed rats. The biological and practical implications of our results are discussed.

Ciprofloxacin pharmacokinetics in dogs following oral administration.

This paper reports the variation of the pharmacokinetic parameters of ciprofloxacin (CIP) following oral administration of three single doses (10, 20 and 40 mg/kg body weight (b.w.)) to dogs. Plasma and urine samples were assayed by HPLC. The plasma vs. time data were submitted to classical compartmental kinetic analysis (one-compartment open model with a lag time) and to non-compartmental data analysis. The maximal plasma concentrations attained after administration of 10 and 20 mg/kg were 1.55 and 3.08 mg/l, respectively, and agree with results reported in the literature for this species. The absorption was slower and showed a longer and more variable lag time when the dose increased. The elimination rate was significantly smaller after administration of the 40 mg/kg (0.0014/min) than 10 and 20 mg/kg doses (near 0.0024/min). AUC/D also showed significant differences. The non-linearity of CIP pharmacokinetics after oral administration was demonstrated by fitting the data AUC vs. dose to a quadratic equation.

Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones.

A preliminary study attempting to assess and explain the intestinal absorption of a series of antibacterial 7-piperazinyl-6-fluoroquinolones is presented. The synthesis, n-octanol partition coefficients, intrinsic rat gut in situ absorption rate constants, and in vitro antibacterial activity data found for these homologous compounds are described. A fluorimetric, reverse-phase HPLC method was performed for the quantification of the quinolones in absorption and partition samples. Equations based on two classic biophysical absorption models are given for predicting the intrinsic absorption features of the series according to the partition data or merely single structural parameters. In situ absorption rate constants were found to increase by a factor of 9.7-13.5 for moderately lipophilic derivatives relative to the simplest compound, while antibacterial activity decreased only by a factor of 4. In vivo absorption tests with two representative members of the series were carried out and the results showed a good accordance with those found in situ. This makes these compounds or related ones with similar partition features excellent candidates for further pharmacokinetic and pharmacological testing. The study can serve as an example of how to prevent potential absorption problems associated with the development of new drugs.

Disposition of ciprofloxacin following intravenous administration in dogs.

The pharmacokinetics of ciprofloxacin (CIP) following intravenous administration in dogs have been investigated. The drug was administered at three doses (2.5, 5 and 10 mg/kg body weight) and was assayed in biological fluid samples (plasma and urine) by an HPLC method. The plasma concentration-time curves were best described by a two-compartment open pharmacokinetic model. The drug was widely distributed (Vd(area) almost 3 l/kg), being distributed in the dog more rapidly than in other species (t1/2(lambda 1) 3 min approximately). The elimination half-life (t1/2 lambda 2) was 129-180 min which is similar to values obtained in other species. The unchanged drug eliminated in urine was less than 37% of the administered dose, which is less than the values obtained in humans, calves and pigs. The glomerular filtration rate and the renal clearance of CIP in the dog suggest that renal elimination probably occurs mainly by glomerular filtration. The results showed that the pharmacokinetics of CIP, as in other species, was linear in dogs in the dose range studied.

Intestinal absorption pathway of gamma-aminobutyric acid in rat small intestine.

Intestinal absorption of gamma-aminobutyric acid (GABA), as a model compound for gamma-aminoacids, has not been extensively studied from the kinetic viewpoint. Since data from our laboratory suggested that some competition arises between intestinal absorption of beta-alanine and GABA and since our intent was to maintain the aqueous stagnant diffusion layer in order to approach absorption tests to in vivo physiological conditions, a rat jejunum in situ study was undertaken in order to gain an insight into the mechanism of GABA absorption. In the present paper, results from assays using isotonic perfusion solutions with starting GABA concentrations ranging from 1 to 50 mM are reported. They show that the intestinal absorption of the gamma-aminoacid can be apparently described as a specialized transport mechanism which obeys Michaelis-Menten and first-order kinetics. Parameter values found were Vm = 13.99 +/- 2.37 mM h-1, Km = 3.87 +/- 0.63 mM, and ka(passive) = 0.362 +/- 0.120 h-1. Through the perfusion of 5 mM beta-alanine solutions containing variable concentrations of GABA (from 5 to 50 mM), a partially competitive inhibition of beta-alanine absorption was apparently characterized.

Influence of gamma-aminobutyric acid on baclofen intestinal absorption.

Since previous studies suggested that baclofen absorption in the rat middle intestine was inhibited by beta-alanine and therefore mediated, at least in part, by the beta-aminoacid carrier, we focused our new studies on the analysis of the possible inhibition of the drug by a gamma-aminoacid model compound, gamma-aminobutyric acid (GABA). A rat jejunum in situ study was undertaken in order to evaluate the effect of GABA on baclofen absorption and to establish the inhibition model. Assays using isotonic perfusion solutions of 0.5 mM baclofen with starting GABA concentrations ranging from 0 to 100 mM are reported. The results show that the absorption rate pseudoconstants of the drug decrease at the GABA concentration increases, with a limiting value of 0.65 h-1 (+/- 0.01). A partial competitive inhibition or complete competitive inhibition in the presence of a passive component could define the interaction phenomena between the two substances. Kinetic absorption parameters for GABA in the presence and absence of baclofen (Ki = 5.67 +/- 1.54, Km = 3.87 +/- 0.63) suggest the existence of more than one intestinal carrier system for baclofen or GABA.

Permeation mechanisms through artificial lipoidal membranes and effects of synthetic surfactants on xenobiotic permeability.

Through the use of permeation/lipophilicity correlations, the mechanisms of permeation of selected test compounds across artificial lipoidal membranes of the polysiloxane type, in the absence and in the presence of a nonionic surfactant (Polysorbate 80), are investigated, in order to design "in vitro" conditions and features suitable for reproducing "in vivo" intestinal absorption tests, as well as to validate some conclusions arising from "in situ" rat gut experiments about the effects of the synthetic surfactants on drug and xenobiotic absorption processes. Six 4-alkylanilines showing a perfect homology were used as test compounds. The reported results clearly show that the in situ biophysical absorption (diffusion) models are completely reproduced by in vitro tests, provided that perfect sink conditions are achieved. Further selection of artificial membrane polarity should be necessary, however, in order to exactly equalize in vitro and in situ permeation rates. As far as the synthetic surfactant action on permeability is concerned, our conclusions are similar to those drawn from in situ studies, except that the effect of the surfactant on membrane polarity is much smaller and the micelle-solubilizing effect somewhat larger. The disruption of the aqueous stagnant diffusion layers adjacent to the membranes by the surfactant has been conclusively demonstrated. A clear first-element deviation for aniline, which prevents its inclusion as a term of the tested series, has been observed; this feature should be borne in mind whenever any in vivo/in vitro correlation has to be established.

Nonlinear pharmacokinetics of cefadroxil in the rat.

The pharmacokinetics and bioavailability of cefadroxil in the rat were examined after intravenous and oral administration at three doses (2.5, 10, and 15 mg). Cefadroxil disposition kinetics was clearly nonlinear, with an increase in plasma clearance as the dose increased (2.65 +/- 0.55, 3.17 +/- 0.48, and 3.82 +/- 0.39 ml/min for the three doses assayed). This phenomenon was attributed to a saturable renal tubular reabsorption of the antibiotic. After oral administration, the normalized Cmax was lower for the largest dose (4.6 +/- 0.7 micrograms/ml) than for the other two doses (5.5 +/- 0.5 and 5.4 +/- 0.7 micrograms/ml). Renal excretion of cefadroxil in the rat after intravenous and oral administration was investigated at two level doses (2.5 and 15 mg). No significant differences were found between doses or administration routes, and the mean percentage of dose recovered in the urine for the intravenous and oral routes was 80.7 +/- 6.1% and 76.4 +/- 3.7%, respectively. Cefadroxil bioavailability estimated from plasma levels or from the amounts of drug excreted in the urine was high and ranged from 90% to 100%.

Nonlinearities in amoxycillin pharmacokinetics. I. Disposition studies in the rat.

Several features of amoxycillin pharmacokinetics in man are not well known in spite of the extensive clinical use of the antibiotic. In this paper it is demonstrated that amoxycillin disposition kinetics in rats is clearly nonlinear, and that this may be due mainly to its elimination mechanisms. At different intravenous bolus dose levels, and in steady-state perfusion studies, the most striking feature is an increased renal clearance as dose increases (from 3.5 to 7.0 mg kg-1 for intravenous bolus, and from 4.6 to 20.0 micrograms min-1 for intravenous perfusions). This phenomenon has been attributed to a saturation of the active renal tubular reabsorption of the antibiotic. When the intravenous dose is substantially increased (28.0 mg kg-1 bolus), plasma clearance tends to stabilize, probably because saturation of the active tubular secretion of amoxycillin takes place at these doses. Extrarenal clearance seems to remain linear throughout the entire dose range. On the basis of these observations and a review of selected bibliography, an interpretation of the kinetic disposition behaviour of amoxycillin in man is attempted.

Nonlinearities in amoxycillin pharmacokinetics. II. Absorption studies in the rat.

Most factors influencing amoxycillin oral absorption are, even today, unknown. Since many dosage schedules have been shown to lead to incomplete absorption, it would be desirable to find a suitable animal model where these factors could be studied in depth. In this paper, it is shown that, in the rat, plasma level curves obtained after oral doses of 7 and 28 mg kg-1 are poorly fitted using first-order absorption kinetics and that the best fit is obtained through the use of an input equation combining zero and first-order kinetics. In contrast, plasma level curves found after intraduodenal administration of amoxycillin solutions (7 mg kg-1) are well fitted by first-order input kinetics. It would seem that precipitation of some dose fraction of the orally administered antibiotic may occur in proximal gastrointestinal areas; this plays an important role in absorption profiles and prevents any possible saturation phenomena associated with active intestinal transport of the antibiotic. A comparative study of available human oral data revealed close similarities with those found in rats. As a result, the plasma level curve fitting was greatly improved by the use of the input function described here for the rat. Although oral bioavailability (as assessed from urinary excretion data) is lower in this latter species, the use of suitable correction factors led to superimposable plasma level curves in the two species, as occurred in previously reported disposition studies.

Pharmacokinetics and bioavailability of diclofenac in the rat.

Diclofenac sodium is a widely used drug with interesting absorption and disposition features when administered to laboratory animals. The present study was undertaken to assess the pharmacokinetics of the drug after iv and gastrointestinal dosing to rats. Renal excretion of unchanged drug was negligible, but biliary excretion of the drug (unchanged and conjugated) was detected in bile duct-cannulated rats; it accounted for 27.2 and 31.2% of the total dose following iv and intraduodenal administration, respectively. Most of the drug excreted in the bile was conjugated diclofenac; unchanged drug accounted for only 4.7 and 5.4% of total diclofenac excreted in the bile after iv and intraduodenal dosing, respectively. In normal animals, intestinal absorption of the drug excreted in the bile resulted in higher drug concentrations in plasma than those obtained in bile duct-cannulated rats, but only after 60 min of dosing. When administered directly into the duodenum, diclofenac absorption was extremely fast and the maximum plasma diclofenac concentration was reached within 2 min. After oral dosing, an early peak was also observed, but it was lower than that obtained after intraduodenal dosing: 71% diclofenac bioavailability was found in bile duct-cannulated rats intraduodenally dosed, whereas in normal animals dosed by mouth a bioavailability of 79% was obtained. In normal animals intraduodenally dosed, an apparent bioavailability of 106% was observed. All of these features, particularly the influence of enterohepatic circulation on drug bioavailability, are discussed.

Partially competitive inhibition of intestinal baclofen absorption by beta-alanine, a nonessential dietary aminoacid.

In situ intestinal absorption of baclofen in the rat in the presence of beta-alanine has been investigated. Through the perfusion of 0.50 mM baclofen solutions containing variable concentrations of the aminoacid (from 5 to 100 mM), a partially competitive inhibition of baclofen absorption was characterized: absorption rate pseudoconstants of the spasmolytic drug decrease as beta-alanine concentration increases, until a limiting value is obtained (36.8 per cent of that found for baclofen alone). A computer method was developed in order to calculate parameters governing baclofen absorption in the presence of beta-aminoacid, with the following results: Vm = 11.22 mM h-1; Km = 7.42 mM; Ki = 2.45 mM; alpha = 2.78; r = 0.998. Kinetic absorption parameters for beta-alanine in the presence of 0.50 mM baclofen were also assessed: Vm = 49.88 mM h-1; Km = 12.16 mM; r = 0.998, which, as can be expected, do not significantly differ from those previously found in the absence of the spasmolytic. It is concluded that baclofen and beta-alanine compete for the same intestinal carrier system, although the values of the interaction parameters, particularly Ki, can be more or less biased due to the limitations of the procedure and/or to the existence of some other carrier system for absorption. Possible practical implications of this phenomenon are briefly discussed.

Intestinal absorption kinetics of a series of aminopenicillins and azidocillin. A comparative study in the rat.

Intestinal absorption rate constants of amoxicillin, ampicillin, epicillin, cyclacillin and azidocillin, by means of a static in situ intestinal perfusion method has been estimated. Luminal remaining antibiotic concentrations were determined using a standard microbiological technique. In order to establish statistically better absorption kinetics, five dose levels were used, ranging from 10 to 1000 micrograms/ml, and first order, Michaelis-Menten and combined first-order and Michaelis-Menten differential model equations were fitted to experimental data found for each antibiotic. According to the AIC test, the best equation for absorption kinetics was selected. Amoxicillin and ampicillin absorption mechanisms were better described by combined kinetics, while for cyclacillin and epicillin the most probable kinetics was that of Michaelis-Menten. For azidocillin, the only non-aminopenicillin component of this series, first order kinetics should be statistically selected.

Absorption mechanisms of secondary aliphatic amines in rat colon and small intestine.

This study is intended to be a further and conclusive validation of the bihyperbolic model equation proposed by Plá-Delfina and Moreno to describe passive intestinal absorption mechanisms through the analysis of absorption-lipophilicity correlations for homologous series of xenobiotics and drugs. Secondary aliphatic amines, largely differing from previously tested substances, were selected as model compounds. Evidence is given which demonstrates that a minimum lipophilicity value exists for absorption in small intestine, instead of a maximum, as probabilistic theories predict. Moreover, bihyperbolic equation provides an excellent fit, with AIC figures up to -29. Aqueous pore absorption was small, presumably due to ionic interactions with pore charges (kp approximately 1.0 h-1), whereas membrane penetration was highly lucrative (km approximately 7.4 h-1), thus indicating that some part of the lipophilic ionic species is capable of penetrating "per se" the lipoidal membrane. As model predicts, bihyperbolic equation collapses to monohyperbolic for colonic absorption, where AIC figures up to -39 were found, with a km value of about 4.0 h-1. Membrane absorption efficiency was, surprisingly, similar in colon and small intestine for the tested solutes; it was attributed to the basic character of the compounds associated with working pH and ion absorption. This latter effect would deserve further investigation in oral sustained-release medication with basic drugs having similar pKa values.

Biophysical absorption models for phenyl-alkyl acids in the absence and in the presence of surfactants. Studies in the rat small intestine.

The present study reviews and checks, by means of experimental work, some theoretical principles of a novel absorption-lipophilicity approach (Pl [symbol: see text] 160-Delfina et al., 1987), used to interpret the effects of synthetic surfactants on drug absorption. For this purpose the correlations between intestinal rat gut absorption constants and lipophilicity indexes are analyzed for a group of compounds belonging to a true homologous series (w-phenyl-alkyl carboxylic acids), in the absence and in the presence of polysorbate 80 in the luminal fluid. Evidence is given for the following surfactant actions: (a) at critical micelle concentration (CMC), the surfactant increases membrane polarity and simultaneously nullifies the limiting character of the stagnant aqueous layer adjacent to the membrane; (b) at supramicellar concentrations (SMC) the above actions become almost completely masked by the micellar solubilization of the compounds, which decreases their absorption rate constants. As a consequence of these interactions, correlation between membrane absorption and lipophilicity, which was clearly hyperbolic in free solution, becomes potential in the presence of surfactant at CMC, whereas at SMC a bilinear correlation is found. Pore absorption was much less affected. Mathematical and physiochemical reasons for this behaviour are outlined, and practical implications are briefly discussed.

Kinetics of the intestinal uptake of zinc acexamate in normal and zinc-depleted rats.

The uptake of zinc as acexamic acid salt in the small intestine of the anaesthetized rat was shown to be a two-phase process in normal animals. The first phase is rapid mucosal binding which satisfies the Freundlich isotherm equation and which involves about 30 per cent of the initially perfused zinc. The second phase was characterized as an apparent absorption step which obeys Michaelis-Menten and first-order combined kinetics, with the following parameters: Vm = 6.51 mg h-1; Km = 2.96 mg; ka = 0.306 h-1. In largely non-saturated conditions, an apparent global rate constant of about 2.50 h-1 was calculated. No significant interference due to endogenous zinc excretion into the small intestine was observed during the absorption period. In zinc-deficient animals, the two phases were not so well characterized. Binding was non-linear and apparent absorption efficiency was much greater at high zinc concentrations, so no evidence of saturable kinetics was found, thus confirming the hypothesis of a homeostatic zinc regulation mechanism.

Absorption kinetics of beta-alanine as model compound in rat small intestine.

Contradictory results have been reported on intestinal beta-alanine absorption, although a generalized view is that it could be a passive, nonmediated process. Since previous data from our laboratory suggested that some competition arises between intestinal absorption of the gamma-amino acidic drug baclofen and beta-alanine, a rat jejunum in situ study was undertaken in order to gain insight into the mechanism of beta-alanine absorption. Perfusion solutions with initial beta-alanine concentrations ranging from 0.3 to 56 mM were used. The beta-alanine absorption was clearly identified as a saturable process which obeys Michaelis-Menten equation kinetics, as assessed through two computer-assisted procedures based on differential and integrated forms of this equation. Parameter values found were: Vm = 3.88-4.72 mg.ml-1.h-1 (43.6-52.9 mM.h-1), and Km = 0.97-1.13 mg.ml-1 (10.9-12.7 mM). Statistical analysis does not account for the existence of significant parallel passive diffusion pathways (less than 0.2 h-1).